AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility

Supports production of AbbVie's current and next-generation immunology and neuroscience medicines

AbbVie is set to acquire a medical device manufacturing facility in Tempe, Arizona, from West Pharmaceutical Services. This deal, announced today, also includes associated intellectual property. The acquisition is expected to significantly boost AbbVie's in-house capabilities and capacity for manufacturing drug delivery devices.

AbbVie plans to hire approximately 200 employees at the site and invest more than $175 million to acquire, as well as modernize and fully integrate it into its global manufacturing network. The combination of this acquisition and associated planned investments are part of AbbVie's commitment to expanding its pharmaceutical manufacturing in the United States (U.S.), supporting innovation and improving patient access and outcomes.

"Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the U.S.," said Robert A. Michael, chairman and chief executive officer, AbbVie. "With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients' lives."

The transaction includes the transfer of manufacturing facilities, including multiple production lines, and 3.5 mL on-body injector technology to support production of current and next-generation AbbVie immunology and neuroscience medicines.

The transaction is anticipated to close in mid-2026, subject to closing conditions.